HALISTER: Merck & Co Raises Top End of 2016 EPS View 2c

Merck & Co Raises Top End of 2016 EPS View 2c

(Bloomberg) -- Merck & Co sees 2016 adj EPS $3.65-$3.77, saw $3.60-$3.75 (Feb. 3), est. $3.71 (range $3.62-$3.78).
  • Now anticipates 2016 rev. $39.0b-$40.2b w/ 2% negative impact from FX, saw $38.7b-$40.2b w/ 3% negative FX impact
  • 1Q adj EPS 89c, est. 85c (range 82c-91c)
  • 1Q rev. $9.31b, est. $9.49b (range $9.24b-$9.86b)
    • Januvia/Janumet rev. $1.41b, est. $1.43b
    • Zetia/Vytorin rev. $889m vs $887m y/y
    • Gardasil rev. $378m, est. $374.6m
    • Proquad MMR II, Varivax rev. $357m vs $348m y/y
    • Remicade rev. $349m, est. $379.5m
    • Isentress rev. $340m, est. $359.5m
    • Cubicin rev. $292m, est. $256.8m
    • Keytruda rev. $249m, est. $230.3m
  • CEO says: Business development is “top priority,” actively pursuing via licensing or bolt-on acquisitions; seeing positive signs for Zepatier U.S. commercial introduction
  • Call 8am, (877) 381-5782 pw 75256428; Preview
Link to Statement:
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
MRK US (Merck & Co Inc)
CSL AU (CSL Ltd)
JNJ US (Johnson & Johnson)
4508 JP (Mitsubishi Tanabe Pharma Corp)

To de-activate this alert, click here

UUID: 7947283